帕西雷奥提德作为一线医疗治疗,用于特定患有壮病的患者
Nicoleta C Olarescu1, Anders P Jørgensen1,2, Shahriar Atai1,2
1Section of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway.
Pituitary
|April 11, 2025
概括
第二代体静止素受体连接体 (SRLs) 像沙里奥提德有效控制垂体瘤,并降低生长激素 (GH) 在耐受第一代SRLs的瘤患者.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 神经外科 神经外科
背景情况:
- 巨症的特征是生长激素 (GH) 过多和垂体瘤.
- 治疗通常涉及手术和体静止素受体连接体 (SRL).
- 一些患者对第一代SRLs (兰铁,铁) 呈现耐药性.
研究的目的:
- 评估二代SRLs的发达胺的疗效,对第一代SRLs耐药的患者.
- 评估沙利西对瘤体积,GH和IGF-1水平的影响.
主要方法:
- 对六名具有SRL耐药性的壮病患者的回顾性分析.
- 患者在MRI和稀疏颗粒组织学上具有大型,高强度的瘤.
- 用沙雷胺治疗的时间为3至8个月.
主要成果:
- 在所有患者中,帕西雷奥提德降低了瘤体积.
- 观察到GH和IGF-1水平的显著改善.
- 视野缺陷正常化;在两名需要治疗的患者中发生高血糖症.
结论:
- 帕西雷奥提德在控制对第一代SRLs耐药的大型复杂的垂体瘤方面表现出有效性.
- 它为具有挑战性的壮病病例提供了有价值的治疗选择.
- 这种治疗有助于后续的治疗方式.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
114
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
114
Direct-Acting Cholinergic Agonists: Therapeutic Uses
638
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
638
Parkinson's Disease: Treatment
158
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
184
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
184
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
96
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
96


